Glucose metabolism in C-1300 neuroblastoma cells after inhibition of hexose monophosphate pathway.
1. Application of 6-AN (0.01 mg/ml) leads to a strong accumulation of 6-PG in C-1300 neuroblastoma cells which, however, only amounts to one third of that found in C-6 glial cells. 2. In C-1300 neuroblastoma cells dephosphorylation of the accumulated 6-PG causes a rise of the intracellular gluconate to eight times the value found for 6-PG. It is four times higher than the gluconate content observed in C-6 glial cells. 3. Although 6-PG is a competitive inhibitor of PGI it causes no reduction of glycolytic flux and ATP content in stationary phase C-1300 neuroblastoma cells in contrast to the strong reduction of glycolytic flux and ATP content observed in C-glial cells. 4. The intracellular Glc-6-P and Fru-6-P content of C-1300 neuroblastoma cells increases by four to five times after treatment with 6-AN. Both this increase and the decrease of Fru-1,6-P2 content point to an inhibition of the phosphofructokinase. 5. In contrast to C-6 glial cells no morphological changes could be observed in C-1300 neuroblastoma cells up to 24 h after administration of 6-AN.
D015120:6-Aminonicotinamide / Q000494:pharmacology; D000818:Animals; D001254:Astrocytoma / Q000378:metabolism; D002460:Cell Line; D005942:Gluconates / Q000096:biosynthesis; D005947:Glucose / Q000378:metabolism*; D006019:Glycolysis / Q000187:drug effects; D006600:Hexosephosphates / Q000378:metabolism*; D051379:Mice; D009374:Neoplasms, Experimental / Q000378:metabolism; D009447:Neuroblastoma / Q000378:metabolism*; D009457:Neuroglia / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D051381:Rats
D005942:Gluconates; D006600:Hexosephosphates; D015120:6-Aminonicotinamide; D005947:Glucose